# OnCo record hypomagnesaemia-on-egfr-antibodies (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/hypomagnesaemia-on-egfr-antibodies/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "hypomagnesaemia-on-egfr-antibodies" ;
  schema:name "Low magnesium on cetuximab and panitumumab: monitoring and replacement"@en ;
  schema:alternateName "cetuximab hypomagnesaemia"@en, "panitumumab hypomagnesaemia"@en, "EGFR antibody hypomagnesemia"@en, "magnesium wasting on anti-EGFR antibodies"@en, "low magnesium on Erbitux"@en, "low magnesium on Vectibix"@en, "electrolyte monitoring on cetuximab"@en, "magnesium replacement during cetuximab"@en ;
  schema:description "Cetuximab and panitumumab make the kidneys lose magnesium, and the level tends to fall the longer treatment goes on. Blood magnesium, calcium and potassium are checked before, during and for about 8 weeks after treatment. Low levels are treated with magnesium tablets or a drip. Tell your team about cramp, tingling or numbness, palpitations or feeling faint. Your team's plan comes first."@en ;
  schema:url <https://onco.cc/protocols/hypomagnesaemia-on-egfr-antibodies/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:related <https://onco.cc/technologies/magnesium-supplements/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/panitumumab/> ;
  onco:terms <https://onco.cc/terms/qt-prolongation/> .
